FXR NR1H4 nuclear receptor binding compounds

US7098336B2 · kind B2 · utility

Assignee

• PHENEX PHARMACEUTICALS AG · DE

Inventors

• Ulrike Bauer · Sandhausen, DE
• Zach Cheruvallath · San Diego, US
• Ulrich Deuschle · Bammental, DE
• Elena Dneprovskaia · San Diego, US
• Tim Gahman · Encinitas, US
• Kristina Giegrich · Lampertheim, DE
• Ronnie Hanecak · San Clemente, US
• Normand Hebert · Irvine, US
• John S. Kiely · San Diego, US
• Ingo Kober · Groß-Gerau, DE
• Manfred Kögl · Eppelheim, DE
• Harald Kranz · Leimen, DE
• Claus Kremoser · Heidelberg, DE
• Matthew Lee · Calabasas, US
• Kerstin Otte · Heidelberg, DE
• Carlton Sage · Irvine, US
• Manish Sud · San Diego, US

Key dates

• Filing date: Aug 13, 2002
• Grant date: Aug 29, 2006
• Expiry date: Aug 13, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/11
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention provides compounds according to the general formula (1) which bind to the NR1H4 receptor and act as agonists, antagonists or mixed agonists/antagonists of the NR1H4 receptor. The invention further provides methods of treating diseases and/or conditions through binding of the nuclear receptor by the compounds and the production of medicaments using the compounds.